Panacur 10 % w/v Oral Suspension

Šalis: Airija

kalba: anglų

Šaltinis: HPRA (Health Products Regulatory Authority)

Veiklioji medžiaga:

Fenbendazole

Prieinama:

Intervet Ireland Limited

ATC kodas:

QP52AC13

INN (Tarptautinis Pavadinimas):

Fenbendazole

Dozė:

10 percent weight/volume

Vaisto forma:

Oral suspension

Recepto tipas:

POM: Prescription Only Medicine as defined in relevant national legislation

Farmakoterapinė grupė:

Cattle, Horses

Gydymo sritis:

fenbendazole

Terapinės indikacijos:

Endoparasiticide

Autorizacija statusas:

Authorised

Leidimo data:

1999-10-01

Prekės savybės

Health Products Regulatory Authority
26 October 2017
CRN000WL0
Page 1 of 6
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Panacur 10 % w/v Oral Suspension
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains
​
​
ACTIVE SUBSTANCE
​
​
Fenbendazole
100
mg
EXCIPIENTS
​
​
Sodium Methyl Parahydroxybenzoate
2.000
mg
Sodium Propyl Parahydroxybenzoate
0.216
mg
Benzyl alcohol
4.835
mg
For a full list of excipients see section 6.1.
3 PHARMACEUTICAL FORM
Oral suspension
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Horses and cattle
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of immature and mature stages of nematodes of the
gastro-intestinal and respiratory tracts of cattle and horses
including encysted
mucosal small redworm larvae in horses. Panacur has an ovicidal effect
on
roundworm eggs. Also effective against cestodes in cattle.
For the treatment of horses infected with adult large strongyles and
adult and larval
small strongyles. Also controls ascarids and oxyurids species.
For the treatment of cattle infected with adult and immature stages
of:
_Haemonchus _spp., _Ostertagia _spp., _Trichostrongylus _spp.,
_Cooperia _spp., _Nematodirus _
spp., _Bunostomum _spp., _Trichuris _spp., _Strongyloides _spp.,
_Oesophagostomum _spp.,
_Capillaria _spp., _Dictyocaulus _spp.
Used at the recommended dose and time, Panacur is effective against
inhibited
larvae of _Ostertagia _spp. and against _Moniezia _spp. of tapeworm.
Health Products Regulatory Authority
26 October 2017
CRN000WL0
Page 2 of 6
4.3 CONTRAINDICATIONS
Do not use in cases of hypersensitivity to the active substance or to
any of the
excipients.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Care should be taken to avoid the following practices because they
increase the risk
of development of resistance and could ultimately result in
ineffective therapy:
• Too frequent and repeated use of anthelmintics from the same
class, over an
extended period of time.
• Underdosing, which may be due to underestimation of body weight,
misadmi